These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 8398293)

  • 1. Comparative effects of clodronate and calcitonin on bone in metastatic breast cancer: a histomorphometric study.
    Taube T; Elomaa I; Blomqvist C; Beneton MN; Kanis JA
    Eur J Cancer; 1993; 29A(12):1677-81. PubMed ID: 8398293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
    Plosker GL; Goa KL
    Drugs; 1994 Jun; 47(6):945-82. PubMed ID: 7521833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of skeletal disease in breast cancer: a controlled clodronate trial.
    Elomaa I; Blomqvist C; Porkka L; Lamberg-Allardt C; Borgström GH
    Bone; 1987; 8 Suppl 1():S53-6. PubMed ID: 2961355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skeletal response to clodronate in prostate cancer with bone metastases.
    Fernández-Conde M; Alcover J; Aaron JE; Ordi J; Carretero P
    Am J Clin Oncol; 1997 Oct; 20(5):471-6. PubMed ID: 9345330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of clodronate on bone in metastatic prostate cancer. Histomorphometric report of a double-blind randomised placebo-controlled study.
    Taube T; Kylmälä T; Lamberg-Allardt C; Tammela TL; Elomaa I
    Eur J Cancer; 1994; 30A(6):751-8. PubMed ID: 7917532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of clodronate on immobilization bone loss.
    Minaire P; Depassio J; Berard E; Meunier PJ; Edouard C; Pilonchery G; Goedert G
    Bone; 1987; 8 Suppl 1():S63-8. PubMed ID: 2961357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease.
    Brown JE; McCloskey EV; Dewar JA; Body JJ; Cameron DA; Harnett AN; Ruutu M; Purohit OP; Tähtelä R; Coleman RE
    Calcif Tissue Int; 2007 Nov; 81(5):341-51. PubMed ID: 17874331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clodronate: the potential for the future.
    Powles T
    Bone; 1991; 12 Suppl 1():S43-4. PubMed ID: 1720014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Dichloromethylene diphosphonate in the treatment of lytic bone metastases].
    Chantraine A; Jung A; van Ouwenaller C; Donath A
    Presse Med; 1984 Feb; 13(8):479-82. PubMed ID: 6230629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases.
    O'Rourke N; McCloskey E; Houghton F; Huss H; Kanis JA
    J Clin Oncol; 1995 Apr; 13(4):929-34. PubMed ID: 7707121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous clodronate for the treatment of hypercalcaemia in breast cancer patients with bone metastases--a prospective randomised placebo-controlled multicentre study.
    Rotstein S; Glas U; Eriksson M; Pfeiffer P; Hansen J; Söderqvist J; Bandmann U; Strid S
    Eur J Cancer; 1992; 28A(4-5):890-3. PubMed ID: 1388038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-year oral clodronate treatment does not impair mineralization of newly formed bone--a histomorphometric study.
    Saarto T; Taube T; Blomqvist C; Vehmanen L; Elomaa I
    Calcif Tissue Int; 2005 Aug; 77(2):84-90. PubMed ID: 16075363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.
    Paterson AH; Powles TJ; Kanis JA; McCloskey E; Hanson J; Ashley S
    J Clin Oncol; 1993 Jan; 11(1):59-65. PubMed ID: 8418243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton.
    Siris ES; Hyman GA; Canfield RE
    Am J Med; 1983 Mar; 74(3):401-6. PubMed ID: 6219577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of dichloromethylene diphosphonate in patients with osteolytic bone metastases and coincident primary hyperparathyroidism.
    Elomaa I; Blomqvist C; Porkka L; Holmström T; Laine H
    Cancer Treat Rep; 1984 Apr; 68(4):655-7. PubMed ID: 6231989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction in new metastases in breast cancer with adjuvant clodronate treatment.
    Diel IJ; Solomayer EF; Costa SD; Gollan C; Goerner R; Wallwiener D; Kaufmann M; Bastert G
    N Engl J Med; 1998 Aug; 339(6):357-63. PubMed ID: 9691101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of clodronate in multiple myeloma.
    Delmas PD
    Bone; 1991; 12 Suppl 1():S31-4. PubMed ID: 1835398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tartrate-resistant acid phosphatase (TRAP) as a serum marker for bone resorption in breast cancer patients with bone metastases.
    Tauchert S; di Liberto A; Cordes T; Thill M; Salehin D; Friedrich M
    Clin Exp Obstet Gynecol; 2009; 36(4):219-25. PubMed ID: 20101852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effects of calcitonin and clodronate in hypercalcaemia.
    Ljunghall S; Rastad J; Akerström G
    Bone; 1987; 8 Suppl 1():S79-83. PubMed ID: 2961359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of dichloromethylene diphosphonate in metastatic bone disease.
    Jung A; Chantraine A; Donath A; van Ouwenaller C; Turnill D; Mermillod B; Kitler ME
    N Engl J Med; 1983 Jun; 308(25):1499-501. PubMed ID: 6222257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.